Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: An open-label phase 2a study

Pediatric Dermatology

Volumn 33, Issue 2, 2016, Pages 150-159

  Tom, Wynnis L ^a   Van Syoc, Merrie ^b   Chanda, Sanjay ^b   Zane, Lee T ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRISABOROLE; BORON DERIVATIVE; FUSED HETEROCYCLIC RINGS; OINTMENT; PHOSPHODIESTERASE IV INHIBITOR;

ADOLESCENT; APPLICATION SITE DERMATITIS; APPLICATION SITE PAIN; AREA UNDER THE CURVE; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; RISK ASSESSMENT; TREATMENT OUTCOME; CLINICAL TRIAL; DERMATITIS, ATOPIC; DRUG TOLERANCE; OINTMENT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; BORON COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CHILD; DERMATITIS, ATOPIC; DRUG TOLERANCE; FEMALE; HUMANS; MALE; OINTMENTS; PHOSPHODIESTERASE 4 INHIBITORS;

EID: 84955311980     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12780     Document Type: Article

References (24)

1. Eichenfield LF, Tom WL, Berger TG, et al., Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116-132.
2. Bieber T,. Atopic dermatitis. N Engl J Med 2008; 358: 1483-1494.
3. Akdis CA, Akdis M, Bieber T, et al., Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118: 152-169.
4. O'Toole A, Thomas B, Thomas R,. The care triangle: determining the gaps in the management of atopic dermatitis. J Cutan Med Surg 2013; 17: 276-282.
5. Ellison JA, Patel L, Ray DW, et al., Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics 2000; 105: 794-799.
6. Hengge UR, Ruzicka T, Schwartz RA, et al., Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006; 54: 1-15.
7. Addendum: Update on Calcineurin Inhibitor Pediatric Literature Review. U.S. Food and Drug Administration, 2011 [online]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM255140.pdf. (accessed August 31, 2015).
8. Arellano FM, Wentworth CE, Arana A, et al., Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-816.
9. Margolis DJ, Abuabara K, Hoffstad OJ, et al., Association between malignancy and topical use of pimecrolimus. JAMA Dermatol 2015; 151: 594-599.
10. Legendre L, Barnetche T, Mazereeuw-Hautier J, et al., Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol 2015; 72: 992-1002.
11. Dastidar SG, Rajagopal D, Ray A,. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007; 8: 364-372.
12. Baumer W, Hoppmann J, Rundfeldt C, et al., Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007; 6: 17-26.
13. Freund YR, Akama T, Alley MR, et al., Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett 2012; 586: 3410-3414.
14. Higgs G,. Is PDE4 too difficult a drug target? Curr Opin Investig Drugs 2010; 11: 495-498.
15. Akama T, Baker SJ, Zhang YK, et al., Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 2009; 19: 2129-2132.
16. Nazarian R, Weinberg JM,. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs 2009; 10: 1236-1242.
17. Hanifin JM, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980; 60: 44-47.
18. Apremilast [package insert]. Summit, NJ: Celgene, 2014.
19. Roflumilast [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2015.
20. Papp K, Reich K, Leonardi CL, et al., Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49.
21. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al., Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73: 1020-1026.
22. Martinez FJ, Calverley PM, Goehring UM, et al., Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015; 385: 857-866.
23. Murrell DF, Gebauer K, Spelman L, et al., Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol 2015; 14: 1108-1112.
24. Stein Gold LF, Spelman L, Spellman MC, et al., A phase 2, randomized, controlled, dose-ranging study evaluating AN2728 topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol 2015; 14: 611-616.